QLife (QLIFE) Q4 2025 earnings summary

Executive summary

• 2025 marked a shift from technology potential to tangible product momentum, with strengthened operations and a clearer commercial focus entering 2026.

• Strategic partnership with Hipro advanced, including an exclusive commercial agreement for EU and US distribution rights.

• Breakthrough clinical validation for the Egoo platform, especially in PKU and diabetes, expands future market opportunities.

• Pharmacy-based blood testing pilots in Nordic countries are set to accelerate adoption and recurring revenue.

• A SEK 31.4 million rights issue is planned to support commercialization and regulatory progress.

Financial highlights

• Q4 2025 revenue was KSEK 49, nearly flat year-over-year (KSEK 50 in Q4 2024).

• EBITDA improved to KSEK -1,615 from KSEK -8,421 year-over-year; net loss narrowed to KSEK -2,334 from KSEK -7,106.

• Full-year 2025 revenue was KSEK 324, up from KSEK 50 in 2024.

• Cash flow for Q4 was KSEK -1,394; year-end cash reserves were KSEK 1,417.

• Earnings per share for Q4 was SEK -0.15, compared to SEK -0.12 in Q4 2024.

Outlook and guidance

• Focus for 2026 is on accelerating commercialization through Hipro distribution, pharmacy channels, and clinical partnerships.

• Regulatory milestones, especially for PHE and metabolic biomarkers, are prioritized.

• Progress toward an approved, sustainable RTO structure with Nasdaq remains a key objective.